General Information of Drug (ID: DMFE3CT)

Drug Name
Alniditan
Synonyms
UNII-B57Z82EOGE; B57Z82EOGE; 152317-89-0; [3H]alniditan; Alniditan [INN:BAN]; N-[[(2R)-chroman-2-yl]methyl]-N'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine; AC1Q4UFC; AC1L24EQ; GTPL117; GTPL120; SCHEMBL717887; CHEMBL88240; ZINC1536693; PDSP2_001383; PDSP1_001399; BDBM50403503; CS-6739; HY-101698; 2-((3-(((R)-2-Chromanylmethyl)amino)propyl)amino)-1,4,5,6-tetrahydropyrimidine; Pasmigren; R-091274
Indication
Disease Entry ICD 11 Status REF
Migraine 8A80 Discontinued in Phase 3 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 302.4
Logarithm of the Partition Coefficient (xlogp) 2
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 3
Chemical Identifiers
Formula
C17H26N4O
IUPAC Name
N-[[(2R)-3,4-dihydro-2H-chromen-2-yl]methyl]-N'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine
Canonical SMILES
C1CNC(=NC1)NCCCNC[C@H]2CCC3=CC=CC=C3O2
InChI
InChI=1S/C17H26N4O/c1-2-6-16-14(5-1)7-8-15(22-16)13-18-9-3-10-19-17-20-11-4-12-21-17/h1-2,5-6,15,18H,3-4,7-13H2,(H2,19,20,21)/t15-/m1/s1
InChIKey
QVSXOXCYXPQXMF-OAHLLOKOSA-N
Cross-matching ID
PubChem CID
66004
CAS Number
152317-89-0
TTD ID
D0Y0RW

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1B receptor (HTR1B) TTK8CXU 5HT1B_HUMAN Agonist [2]
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Agonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 120).
2 Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol. 1998 Apr;123(8):1655-65.